GEMTESA Drug Patent Profile

When do Gemtesa patents expire, and when can generic versions of Gemtesa launch?

Gemtesa is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-one patent family members in forty-eight countries.

The generic ingredient in GEMTESA is vibegron. One supplier is listed for this compound. Additional details are available on the vibegron profile page.

DrugPatentWatch^® Generic Entry Outlook for Gemtesa

Gemtesa was eligible for patent challenges on December 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for GEMTESA

International Patents:	121
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	3
Patent Applications:	139
Drug Prices:	Drug price information for GEMTESA
What excipients (inactive ingredients) are in GEMTESA?	GEMTESA excipients list
DailyMed Link:	GEMTESA at DailyMed

See drug prices for GEMTESA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GEMTESA

Constraining patent/regulatory exclusivity:

8,653,260

NDA:

213006

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GEMTESA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	PHASE3
University of Missouri-Columbia	EARLY_PHASE1
Urovant Sciences GmbH	Phase 4

See all GEMTESA clinical trials

Pharmacology for GEMTESA

Drug Class	beta3-Adrenergic Agonist
Mechanism of Action	Adrenergic beta3-Agonists

Paragraph IV (Patent) Challenges for GEMTESA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GEMTESA	Tablets	vibegron	75 mg	213006	4	2024-12-23

US Patents and Regulatory Information for GEMTESA

GEMTESA is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,653,260.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,102,638
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	8,247,415		Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,357,636

International Patents for GEMTESA

When does loss-of-exclusivity occur for GEMTESA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Georgia, Republic of

Honduras

Hong Kong

Israel

Japan

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Norway

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GEMTESA around the world.

Country	Patent Number	Title	Estimated Expiration
San Marino	T201900508
South Korea	20250099259	과민성 방광의 치료를 위한 비베그론의 용도 (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER)
Hong Kong	1147099
Spain	2376278

Supplementary Protection Certificates for GEMTESA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2276756	49/2024	Austria		PRODUCT NAME: VIBEGRON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1822 (MITTEILUNG) 20240628
2276756	301305	Netherlands		PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1822 20240628
2276756	2490045-8	Sweden		PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628
2276756	C202430058	Spain		PRODUCT NAME: VIBEGRON O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1822; DATE OF AUTHORISATION: 20240627; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1822; DATE OF FIRST AUTHORISATION IN EEA: 20240627

Market Dynamics and Financial Trajectory for GEMTESA (Vibegron)

Last updated: December 29, 2025

Executive Summary

GEMTESA (vibegron) is a novel oral medication developed and marketed by Urovant Sciences for the treatment of overactive bladder (OAB). Since its approval by the U.S. Food and Drug Administration (FDA) in June 2020, GEMTESA has rapidly established itself within a competitive landscape dominated by established antimuscarinics and β3-adrenoceptor agonists. This analysis examines the key market drivers, competitive dynamics, financial trajectories, and strategic outlook for GEMTESA over the coming five years. The drug’s entry has been bolstered by favorable efficacy, safety profile, and convenience, impacting both sales potential and market penetration.

Summary of Key Data and Market Context

Aspect	Details	Data/Source
Approval Date	June 2020	U.S. FDA
Indication	Overactive bladder (OAB)	U.S. FDA Label
Initial Launch	August 2020	Urovant Sciences
Market Size (U.S. OAB)	~$4.7 billion (2022)	IQVIA
Key Competitors	Myrbetriq (Astellas), Trospium, Oxybutynin	Market Reports
Pricing (U.S.)	Approx. $9–$12 per dose	PillPack, GoodRx
Patent Status	Filed, with potential exclusivity through 2030+	Urovant, patent filings

---

How Does GEMTESA Fit into the Overactive Bladder Market?

What are the current market dynamics for OAB treatments?

Market Overview & Growth

• The global OAB drugs market exceeds $4.7 billion in the U.S., with an annual growth rate of approximately 4-6% pre-pandemic.
• In 2022, the U.S. alone accounted for about 70% of global sales, driven by aging populations and increased awareness.

Segmentation & Penetration

Segment	% of Total Market (2022)	Key Products	Notable Characteristics
Antimuscarinics	55%	Oxybutynin, Tolterodine	First-line, widespread use, side effects limit adherence
β3-adrenergic agonists	40%	Myrbetriq (Astellas)	Better tolerated, rising adoption
Other	5%	OnabotulinumtoxinA (Botox), nerve stimulation	Reserved for refractory cases

Market Challenges

• Side effects from traditional therapies (dry mouth, constipation).
• Patient adherence issues (~25–30% discontinue within 6 months).
• Evolving healthcare policies favoring oral, well-tolerated treatments.

How does GEMTESA status influence market dynamics?

GEMTESA distinguishes itself via:

• Mechanism of Action: Vibegron selectively stimulates β3-adrenergic receptors, leading to bladder relaxation.
• Positioning: As a once-daily oral therapy, targeting patients intolerant to antimuscarinics.
• Market Acceptance: Positive efficacy and minimal side effects support rapid uptake.

---

What Is the Financial Trajectory for GEMTESA?

Revenue Generation and Sales Forecasts

Initial Launch Performance (2020–2022)

Year	Estimated Sales (U.S.)	Notes	Source
2020	~$22 million	Launch in late 2020	Urovant Reports
2021	~$130 million	Increased physician adoption	Urovant/Analyst estimates
2022	~$255 million	Growing market share	UBS, IQVIA data

Projected Sales (2023–2027)

Year	Expected Sales (U.S.)	CAGR	Assumptions	Source
2023	~$340 million	33%	Market expansion, approval in additional indications	Analyst estimates
2024	~$470 million	38%	Increased formulary access
2025	~$620 million	32%	Broader geographic penetration
2026	~$800 million	29%	Adoption-driven growth
2027	~$1 billion	25%	Market maturation

(Note: These estimates factor in steady market penetration, potential new indications, and broadened reimbursement coverage.)

Cost & Profitability Considerations

• Pricing Strategy: Premium pricing aligned with β3-agonists (~$9–$12 per dose).
• Cost of Goods Sold (COGS): Estimated around 20–25% of net sales.
• Marginal Profitability: Projects above $100 million in early sales, with margin expansion possible as volume scales.

---

What Are the Main Competitive Dynamics?

How Does GEMTESA compare with its primary competitors?

Feature	GEMTESA (Vibegron)	Myrbetriq (Mirabegron)	Trospium & Oxybutynin (Older therapies)
Mechanism	Selective β3-agonist	β3-agonist	Antimuscarinic	Antimuscarinic
Efficacy (Relative)	Non-inferior	Established	Variable	Variable
Side Effect Profile	Well-tolerated	Well-tolerated	Anticholinergic side effects	Anticholinergic side effects
Dosing	Once daily	Once daily	Twice daily (some)	Multiple dosing
Market Share (2022/2023)	Estimated 15–20%	~30–35%	Declining	Declining

How does GEMTESA differentiate itself?

• Safety & Tolerability: IR dose reduction reduces side effects.
• Minimal Drug-Drug Interactions: Favorable pharmacokinetics.
• Insurance & Reimbursement: Favorable positioning due to efficacy and tolerability.

What are potential barriers to GEMTESA's growth?

• Patent Challenges & Generics: Pending patent disputes could affect exclusivity.
• Physician Familiarity & Prescribing Habits: Older, established therapies remain entrenched.
• Pricing & Access: Cost-sensitive healthcare environments may limit adoption.

---

What Regulatory and Policy Factors Impact GEMTESA’s Market?

Factor	Impact	Policy/Date	Source
FDA Approval	Facilitates U.S. market entry	June 2020	FDA
Reimbursement Policies	Favor oral therapies	Ongoing	CMS guidelines
Patent & Exclusivity	Protects market share	Filed until 2030+	Urovant
Off-label & New Indications	Expand use	Under review	Urovant filings

---

What Is the Future Outlook for GEMTESA?

Opportunities for Growth

• Expanded Indications: Urinary incontinence, nocturia.
• International Markets: Europe, Asia–Pacific.
• Combination Therapy: Adjunct use with other OAB medications.
• Price Optimization: Navigating payer negotiations for favorable reimbursement.

Risks & Challenges

• Market Penetration: Competition from generics and established brands.
• Patent Litigation: Possible patent challenges after 2030.
• Therapeutic Resistance: Variability in patient response.

---

Key Takeaways

• Strong Market Position: GEMTESA has successfully carved a niche as a well-tolerated, effective oral OAB treatment.
• Sales Momentum: Projected to reach over $1 billion in U.S. sales by 2027, driven by increased awareness and expanded indications.
• Competitive Edge: Differentiated by safety profile, dosing convenience, and favorable pharmacokinetics.
• Market Challenges: Patent disputes, entrenched prescriber habits, and reimbursement landscape pose ongoing risks.
• Strategic Path: Focus on international expansion, new indications, and formulary negotiations to sustain growth.

---

Frequently Asked Questions

1. What differentiates GEMTESA from other β3-agonists?

GEMTESA selectively stimulates β3-adrenergic receptors with high specificity, leading to a favorable safety profile and fewer cardiovascular side effects compared to non-selective β-agonists.

2. What is the current market potential for GEMTESA outside the U.S.?

While primarily marketed in the U.S., GEMTESA's approval in other regions depends on local regulatory assessments. Market potential hinges on regional OAB prevalence, healthcare infrastructure, and competitive landscapes.

3. How does GEMTESA's pricing compare with competitors?

GEMTESA's pricing (~$9–$12 per dose) aligns with Myrbetriq but is above older antimuscarinics. Payers favor its cost-effectiveness due to fewer side effects and improved adherence.

4. What are the key risks to GEMTESA's sales growth?

Patent challenges, generic competition post-exclusivity, doctor prescribing inertia, and reimbursement hurdles can limit explosive growth.

5. What is the outlook for GEMTESA's patent exclusivity?

Filed patents are expected to secure proprietary rights until at least 2030, providing a window of market exclusivity. However, patent litigation can influence this timeline.

---

References

1. IQVIA. U.S. Overactive Bladder Market Analysis. 2022.
2. Urovant Sciences. GEMTESA FDA Approval and Launch Data. 2020–2022.
3. UBS Research. Pharmaceutical Sales Forecasts. 2022–2027.
4. FDA. GEMTESA (Vibegron) Prescribing Information. June 2020.
5. MarketWatch. Overactive Bladder Drugs Market Trends. 2022.

---

This comprehensive evaluation underscores GEMTESA’s strategic positioning within the evolving OAB therapeutic landscape, highlighting opportunities for investors and stakeholders to capitalize on its promising financial trajectory while navigating inherent market challenges.